News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BIND Therapeutics Announces Closing of Initial Public Offering


9/26/2013 10:10:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND) announced today the closing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, resulting in gross proceeds of $70,500,000 before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Select Market under the ticker symbol “BIND” on September 20, 2013. Credit Suisse (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Stifel Nicolaus & Company, Incorporated and JMP Securities LLC are acting as co-managers. A registration statement relating to these securities has been filed with, and was declared effective by, the U.S. Securities and Exchange Commission on September 19, 2013. The offering was made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus relating to and describing the terms of the offering can be obtained by eligible investors from their Credit Suisse or Cowen and Company sales representative, or from the Credit Suisse Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: 800-221-1037, Email: newyork.prospectus@credit-suisse.com and from Cowen and Company, LLC c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES